List view / Grid view
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-300x278.jpg)
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-e1642427117214.jpg)
Says the Bay Area building’s digital infrastructure will make it…
Says the Bay Area building’s digital infrastructure will make it one of biopharma’s leading artificial intelligence-powered centres.
As part of its proposed acquisition, Gilead will add a…
As part of its proposed acquisition, Gilead will add a potential best-in-disease treatment for second-line primary biliary cholangitis (PBC) to its liver portfolio.
Gilead’s Sunlenca (lenacapavir) is the first capsid inhibitor to be…
Gilead’s Sunlenca (lenacapavir) is the first capsid inhibitor to be FDA-approved for treating HIV-1.
Gilead’s Sunlenca® (Lenacapavir) was authorised by the European Commission for…
Gilead’s Sunlenca® (Lenacapavir) was authorised by the European Commission for people with multi-drug-resistant HIV who have very limited treatment choices.
With two knighthoods in the last month, here EPR discusses…
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
The new global paediatric drug development centre of excellence will…
The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
The companies have agreed to jointly develop and commercialise long-acting,…
The companies have agreed to jointly develop and commercialise long-acting, investigational treatment combinations of lenacapavir and islatravir for HIV.
Gilead is set to acquire Immunomedics for approximately $21 billion,…
Gilead is set to acquire Immunomedics for approximately $21 billion, with the transaction anticipated to close in the fourth quarter of 2020.
Gilead has announced that the potential COVID-19 drug remdesivir will…
Gilead has announced that the potential COVID-19 drug remdesivir will cost $390 per vial for developed countries, with treatment courses costing $2,340 per patient.
Gilead Sciences has said it will initiate clinical trials in…
Gilead Sciences has said it will initiate clinical trials in August to test an inhaled formulation of remdesivir, a potential COVID-19 therapy.
The US FDA has given emergency use authorisation to remdesivir…
The US FDA has given emergency use authorisation to remdesivir for the treatment of patients in hospital with severe COVID-19.
Gilead's acquisition of Forty Seven was unanimously approved by both…
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
Investment to help meet rising demand for licensed biologics and…
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
3 – 4 December 2013, The InterContinental Park Lane, London...
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
The Medicines Patent Pool and Roche announce an agreement...
5 August 2013 | By Roche
The Medicines Patent Pool and Roche announce an agreement...
